In the last trading session, 1.11 million CorMedix Inc (NASDAQ:CRMD) shares changed hands as the company’s beta touched 1.66. With the company’s per share price at $12.82 changed hands at $0.07 or 0.55% during last session, the market valuation stood at $869.51M. CRMD’s last price was a discount, traded about -8.03% off its 52-week high of $13.85. The share price had its 52-week low at $3.61, which suggests the last value was 71.84% up since then.
Analysts gave the CorMedix Inc (CRMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 1 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRMD as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. CorMedix Inc’s EPS for the current quarter is expected to be 0.12.
CorMedix Inc (NASDAQ:CRMD) trade information
Instantly CRMD was in green as seen at the end of in last trading. With action 10.23%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 58.27%, with the 5-day performance at 10.23% in the green. However, in the 30-day time frame, CorMedix Inc (NASDAQ:CRMD) is 57.49% up.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need a downside of -42.44% from its current market value. According to analyst projections, CRMD’s forecast low is 9 with 9 as the target high. To hit the forecast high, the stock’s price needs a 29.8% surge from its current level, while the stock would need to tank 29.8% for it to hit the projected low.
CorMedix Inc (CRMD) estimates and forecasts
Year-over-year growth is forecast to reach 231.77% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 29.88M. 6 analysts are of the opinion that CorMedix Inc’s revenue for the current quarter will be 35.75M. The company’s revenue for the corresponding quarters a year ago was 806.12k and 11.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3,606.46%. The estimates for the next quarter sales put growth at 212.07%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 29.80%. The 2025 estimates are for CorMedix Inc earnings to increase by 365.00%.
CRMD Dividends
CorMedix Inc is expected to release its next quarterly earnings report in June.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.0373% or 2.9 million shares worth $12.57 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.73 shares estimated at $22.2 million under it, the former controlled 2.55% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.37% of the shares, roughly 1.61 shares worth around $20.58 million.
